[1]Budinska E., Popovici V., Tejpar S. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol. 2013;231:63-76.
[2]De Sousa E.M.F., Wang X., Jansen M. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19:614-618.
[3]Marisa L., de Reynies A., Duval A. Gene expression classification of colon cancer into molecular subtypes : characterization, validation, and prognostic value. PLoS Med. 2013;10:e1001453.
[4]Roepman P., Schlicker A., Tabernero J. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014;134:552-562.
[5]Sadanandam A., Lyssiotis C.A., Homicsko K. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19:619-625.
[6]Schlicker A., Beran G., Chresta C.M. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics. 2012;5:66.
[7]Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015 ; 21 : 1350-6.
[8]Becht E, de Reynies A, Giraldo NA, et al. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clin Cancer Res 2016 ; 22 : 4057-66.
[9]Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015 ; 372 : 2509-20.
[10]Dalerba P., Sahoo D., Paik S. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med. 2016;374:211-222.
[11]Pilati C., Taieb J., Balogoun R. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. Ann Oncol. 2017;28:1032-1035.